

TABLES

Table 1: Patient' characteristics

Characteristics	Mean ($\pm$ DS) or n (%)	Median (IQR) or n (%)
Patients	267	267
Age (yrs)	72 $\pm$ 3	70 (63-76)
BMI (Kg/m ²)	26 $\pm$ 3	25 (24-29)
ASA Score		
1	6/267 (2%)	6/267 (2%)
2	106/267 (40%)	106/267 (40%)
3	151/267 (57%)	151/267 (57%)
4	4/267 (1%)	4/267 (1%)
5	0/267 (0%)	0/267 (0%)
Neutrophil Count	4,5 $\pm$ 0.8	4,1 (3,3-5,2)
Lymphocyte Count	1,7 $\pm$ 5	1,8 (1,4-2,2)
NLR Ratio	2,5 $\pm$ 0,7	2,3 (1,8-3,2)
Monocyte Count	0.49 $\pm$ 0.11	0,48 (0,37-0,68)
MLR Ratio	0.3 $\pm$ 0.1	0,3 (0,2-0,3)
Platelet Count	240 $\pm$ 30	240 (210-280)
PLR Ratio	220 $\pm$ 10	218 (210-231)
Fibrinogen levels	290 $\pm$ 50	303 (37-375)
Albumin levels	4,60 $\pm$ 0,20	4,60 (4,40-4,80)
Bladder surgery		
- Mono UC	13/267 (5%)	13/267 (5%)
- Bilateral UCS	107/267 (40%)	107/267 (40%)
- Ileal conduct	121/267 (45%)	121/267 (45%)
- Neobladder	26/267 (10%)	26/267 (10%)
Stage		
1	27/267 (10%)	27/267 (10%)
2	123/267 (46%)	123/267 (46%)
3	90/267 (34%)	90/267 (34%)

4	17/267 (5%)	17/267 (5%)
sFI score≥3	50/267 (19%)	50/267 (19%)

Table 2: Non advanced (pT<3a) vs advanced disease (pT≥3a)

Variable	Non-Advanced Disease	Advanced Disease	p value
Patients	139 (52%)	128 (48%)	0,43
Age	70 (59/81)	71 (60/85)	0,23
BMI (kg/m ²)	26 (24,3/28,4)	26,9 (23,9/30)	0,65
ASA Score			
1	3/267 (2%)	3/267 (2%)	0,52
2	55/267 (21%)	51/267 (19%)	0,32
3	79/267 (30%)	72/267 (27%)	0,78
4	2/267 (1%)	2/267 (1%)	0,98
5	0/267 (0%)	0/267 (0%)	0,99
Neutrophil count	3,8 (3,1/5,1)	4,1 (3,3/5,2)	0,23
Lymphocyte Count	1,8 (1,5/2,2)	1,7 (1,3/2,1)	0,36
NLR	212,5 (163,5/286,4)	230 (184,9/306,7)	0,12
Monocyte count	0,49 (0,38/0,59)	0,49 (0,35/0,58)	0,64
MLR	24,6 (20,4/32,1)	26,1 (21,6/35,7)	0,24
Platelet count	135 (120/156)	129 (127/134)	0,49
PLR	218 (192/262,5)	215 (182/271)	0,32
Fibrinogen	301 (274,5/356)	322 (266/373)	0,02
Albumin	46 (4,7/48)	46 (4,3/48)	0,09
PSA	6,7 (5/8,9)	8,2 (5,9/12,3)	0,03
Bladder surgery	139/267 (52%)	128/267 (48%)	0,43
- Mono UC	8/267 (3%)	5/267 (2%)	0,55

- Bilateral UCS	57/267 (21%)	50/267 (19%)	0,39
- Ileal conduct	64/267 (24%)	57/267 (21%)	0,44
- Neobladder	10/267 (5%)	7/267 (4%)	0,57
Clavien Dindo			
1	78 (49%)	80 (46%)	0.29
2	53 (34%)	55 (32%)	0.28
3	16 (10%)	19 (11%)	0.43
4	6 (4%)	10 (6%)	0.23
5	5 (3%)	9 (5%)	0.19
sFI	1(0/1)	2(0/2)	0,04
CCI	3 (2/4)	5(6/8)	0,03

Table 3: Complications' list

	Non advanced (pT<3a)	Advanced (pT≥3a)	p
Complications	158	173	0.01
Fistulae	2 (1%)	4 (2%)	0.01
Infectious	43 (28%)	49 (29%)	0.02
ileus	12 (8%)	15 (9%)	0.02
Blood clots	8 (5%)	9 (5%)	0.88
Leakage	16 (10%)	17 (10%)	0.79
Abscesses	22 (14%)	24 (15%)	0.57
Ureteral stenosis	11 (7%)	14 (9%)	0.36
Hemorrhage	11 (7%)	16 (10%)	0.12
Metabolic acid-base abnormalities	12 (7%)	12 (8%)	0.55
Hypokaliemic metabolic acidosis	7 (5%)	8 (5%)	0.68
Lithiasis	2 (1%)	3 (2%)	0.67
Dehiscence	2 (2%)	2 (2%)	0.69

Table 4: Univariate and multivariate analysis of risk of advanced stage

	Risk of advanced stage		Risk of advanced stage	
	OR (IQR), p		OR (IQR), p	
Age	1.22 (1.05-1.39)	0.001	1.03 (1.00-1.05)	0.032
sFI	1,35 (0,99-1,88)	0,001	1,50 (1,20-1,88)	0,101
CCI	1.11 (0,61-1,92)	0,001	1.32 (1,13-1,52)	0,367
NLR	0.50 (0.21-1.66)	0.001	1.00 (0.99-1.00)	0.841
MLR	0.56 (0.23-1.98)	0.001	0.99 (0.99-1.00)	0.588
PLR	0.69 (0.33-1.66)	0.001	0.99 (0.99-1.00)	0.213
Fibrinogen	0.77 (0.46-1.74)	0.001	1.00 (0.99-1.00)	0.686

Table 5: Univariate and multivariate analysis of risk of complications

	Risk of Complications Clavien ≥2		Risk of Complications Clavien ≥2	
	OR (IQR), p		OR (IQR), p	
Age	0.63 (0.10-1.45)	0.001	0.99 (0.99-1.00)	0.922
sFI	1,22 (0.90-1,23)	0,001	1.30 (1.03-1,63)	0.524
CCI	1.32 (0,93 - 1,52)	0,001	1.17 (1.01-1.36)	0.214
NLR	0.80 (0.61-1.42)	0.001	1.00 (0.99-1.00)	0.589
MLR	0.59 (0.29-1.50)	0.001	1.00 (0.99-1.01)	0.513
PLR	0.86 (0.61-1.82)	0.001	1.00 (0.99-1.00)	0.456
Fibrinogen	0.89 (0.59-1.40)	0.001	1.40 (1.06-1.86)	0.018